Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELETRIPTAN HYDROBROMIDE vs NARATRIPTAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibition of trigeminal nerve transmission.
Selective serotonin 5-HT1B/1D receptor agonist; binds to these receptors on intracranial blood vessels and trigeminal sensory neurons, causing vasoconstriction and inhibition of neuropeptide release, thereby reducing migraine-related inflammation and pain.
Acute treatment of migraine with or without aura in adults
Acute treatment of migraine with or without aura in adults
40 mg orally once, may repeat after 2 hours if headache recurs; maximum 80 mg/day.
2.5 mg orally at onset of migraine; may repeat after 4 hours if headache recurs, maximum 5 mg per day.
Terminal elimination half-life is approximately 4-5 hours in healthy adults. In patients with hepatic impairment, half-life may be prolonged up to 8 hours. The half-life supports a clinical duration suitable for acute migraine treatment, with no accumulation with single doses.
Terminal elimination half-life is approximately 5–6 hours (range 4–8 hours), supporting a twice-daily dosing interval for acute migraine treatment and allowing once-daily dosing for menstrual migraine prophylaxis.
Primarily metabolized by CYP3A4; also minor contribution from CYP2C9, CYP2C19, and CYP2D6.
Hepatic via cytochrome P450 (CYP) enzymes, primarily CYP3A4, with minor contribution from other isoforms. Metabolites are inactive.
Approximately 90% of the dose is eliminated in feces, with less than 10% recovered in urine. Renal excretion accounts for about 9% of total clearance, primarily as unchanged drug. Biliary/fecal elimination is the major route.
Renal: ~50% (metabolites and unchanged drug); Fecal: ~30%; Biliary: minor; unchanged naratriptan accounts for <10% of urinary recovery.
Approximately 85% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
~29% bound, primarily to albumin.
Volume of distribution is approximately 1.4 L/kg (range 1.0-2.0 L/kg), indicating extensive distribution into tissues beyond total body water.
Approximately 2.4 L/kg (range 1.8–3.0 L/kg), consistent with extensive tissue distribution beyond plasma.
Oral bioavailability is approximately 50% (range 30-70% due to first-pass metabolism) for the tablet formulation. Absolute bioavailability is moderate due to presystemic clearance.
Oral: 74% (range 63–95%); subcutaneous: ~100% (but not marketed).
No dose adjustment required for mild to moderate renal impairment; contraindicated in severe renal impairment (Cr Cl <10 m L/min).
No dose adjustment recommended; however, use with caution in severe renal impairment (Cr Cl <15 m L/min) due to limited data.
Contraindicated in severe hepatic impairment (Child-Pugh C); no adjustment for mild to moderate impairment.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), maximum dose is 2.5 mg per day; do not exceed single dose of 2.5 mg.
Not established; safety and efficacy in patients <18 years not studied.
Safety and efficacy not established in patients under 18 years; no approved pediatric dosing guidelines.
Use with caution due to potential decreased hepatic/renal function; consider lower starting dose (20 mg).
Use with caution due to potential for reduced hepatic and renal function; no specific dose adjustment recommended, but start at low end of dosing range (2.5 mg).
No FDA boxed warning.
Naratriptan is contraindicated in patients with ischemic heart disease or coronary artery vasospasm due to risk of myocardial ischemia/infarction and cerebrovascular events.
Coronary artery vasospasm and ischemic heart disease,Cerebrovascular events (stroke, transient ischemic attack),Life-threatening serotonin syndrome (especially with SSRIs/SNRIs),Hypertensive crisis in patients with uncontrolled hypertension,Risk of myocardial ischemia in patients with risk factors
Cardiac events: risk of myocardial ischemia, infarction, and arrhythmias,Cerebrovascular events: stroke, subarachnoid hemorrhage,Serotonin syndrome: especially with concomitant serotonergic drugs,Medication overuse headache: chronic use can lead to daily headaches,Severe hepatic impairment: reduce dose or avoid,Severe renal impairment: contraindicated
History of ischemic heart disease or coronary artery vasospasm,Uncontrolled hypertension,Hemiplegic or basilar migraine,Use within 24 hours of another triptan or ergotamine,Concurrent use of MAO inhibitors or within 2 weeks of discontinuation,Severe hepatic impairment (Child-Pugh C)
Ischemic heart disease (angina, history of MI, silent ischemia),Coronary artery vasospasm (Prinzmetal's angina),History of stroke or transient ischemic attack,Uncontrolled hypertension,Hemiplegic or basilar migraine,Severe hepatic impairment (Child-Pugh C),Severe renal impairment (Cr Cl <15 m L/min),Concurrent use of ergotamine derivatives or other 5-HT1 agonists within 24 hours,Hypersensitivity to naratriptan or any component
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4, increasing eletriptan exposure and risk of adverse effects. No other significant food interactions reported.
No significant food interactions. However, grapefruit juice may theoretically increase naratriptan exposure via CYP1A2 inhibition; avoid concurrent intake of large quantities. Alcohol may exacerbate migraine symptoms and should be avoided during an attack.
Limited human data; animal studies show no teratogenicity at clinically relevant doses. First trimester: risk cannot be excluded; second/third trimester: no known increased risk. Avoid in third trimester due to possible uterine atony or decreased placental perfusion.
FDA Pregnancy Category C. Animal studies show fetal toxicity (increased resorptions, skeletal anomalies) at maternotoxic doses. No adequate human studies. Avoid in first trimester unless benefit outweighs risk. Second/third trimester: limited data; use only if clearly needed.
Excreted into breast milk in low amounts (M/P ratio unknown). Relative infant dose estimated at <1% of maternal weight-adjusted dose. Considered compatible with breastfeeding; monitor infant for irritability and sleep disturbance.
Unknown if excreted in human milk; M/P ratio not established. Due to low molecular weight (335.46 g/mol), excretion is possible. Caution advised; monitor infant for adverse effects (e.g., drowsiness, diarrhea).
No specific dose adjustment recommended; pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may reduce efficacy, but standard dosing remains safe. Consider lowest effective dose.
No specific pharmacokinetic data in pregnancy. Increased plasma volume and renal clearance in pregnancy may reduce drug exposure; however, lack of safety data precludes dose adjustments. Use lowest effective dose for shortest duration.
Eletriptan has higher lipophilicity and longer half-life than sumatriptan, potentially offering better CNS penetration and sustained efficacy. Contraindicated within 24 hours of other triptans or ergotamines. Avoid in patients with severe hepatic impairment (Child-Pugh C) as metabolism is CYP3A4-dependent. Maximum single dose 40 mg; may repeat after 2 hours if no response, but do not exceed 80 mg/day. Onset typically within 30 minutes; if first dose fails, consider alternative therapy for subsequent attacks.
Naratriptan has a longer half-life (~6 hours) and higher oral bioavailability (70%) compared to sumatriptan, making it suitable for patients with prolonged migraine attacks or those requiring sustained relief. It is contraindicated in patients with a history of ischemic heart disease, cerebrovascular disease, or uncontrolled hypertension due to vasoconstrictive effects. Use within 4 hours of migraine onset for optimal efficacy; do not use for prophylaxis. Monitor for serotonin syndrome when co-administered with other serotonergic drugs.
Take at the first sign of migraine headache, not for prevention.,Do not take more than 80 mg in 24 hours; wait at least 2 hours between doses.,Avoid taking within 24 hours of other triptans or ergotamine medications.,Report chest pain, palpitations, or shortness of breath immediately.,Do not use if you have uncontrolled high blood pressure, coronary artery disease, or history of stroke.,Grapefruit juice may increase drug levels; avoid consumption during treatment.,Swallow tablet whole; do not crush or chew.
Take naratriptan at the first sign of migraine headache; do not use to prevent migraines.,Do not exceed one tablet (2.5 mg) within 24 hours; do not take more than 2 tablets in any 24-hour period.,Seek emergency medical attention if you experience chest pain, shortness of breath, or sudden severe abdominal pain after taking this medication.,Inform your doctor if you have heart disease, high blood pressure, liver or kidney problems, or if you are pregnant or breastfeeding.,Avoid using naratriptan within 24 hours of other triptans or ergotamine-containing medications.
"Eletriptan, a 5-HT1B/1D receptor agonist used for migraine, and ondansetron, a 5-HT3 receptor antagonist antiemetic, both increase serotonergic activity via different mechanisms. Concurrent use may lead to excessive serotonin accumulation, potentially triggering serotonin syndrome, characterized by neuromuscular excitation, autonomic instability, and altered mental status. While the interaction is mechanistically plausible, clinical reports are rare, and caution is advised particularly in patients on multiple serotonergic agents."
"Concomitant use of eletriptan, a 5-HT1B/1D receptor agonist, with maprotiline, a tetracyclic antidepressant that inhibits serotonin reuptake, may result in additive serotonergic effects. This increases the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. Patients combining these agents require close monitoring for symptoms such as hyperthermia, clonus, hyperreflexia, and agitation."
"Concomitant use of eletriptan and almotriptan, both triptan-class 5-HT1B/1D receptor agonists, increases the risk of serotonin syndrome and additive vasoconstriction, including coronary vasospasm. Excessive serotonergic activity may lead to neuromuscular excitation, autonomic instability, and altered mental status, while additive arterial vasoconstriction can precipitate severe hypertension or ischemic events, especially in patients with cardiovascular risk factors."
"Concurrent use of naratriptan, a serotonin 5-HT1B/1D receptor agonist, with dapiprazole, an alpha-1 adrenergic receptor antagonist, may lead to additive vasoconstrictive effects on coronary, cerebral, and peripheral vasculature. This synergy increases the risk of severe adverse events such as myocardial ischemia, hypertension, or cerebrovascular complications due to unopposed vasoconstriction from naratriptan and potential reflex sympathetic activation from dapiprazole's alpha blockade. Particularly in patients with underlying cardiovascular risk factors, this combination can precipitate hypertensive crises or ischemic events."
"Concomitant use of naratriptan, a serotonin 5-HT1B/1D receptor agonist, and clozapine, an atypical antipsychotic with potent 5-HT2A receptor antagonism, may lead to additive serotonergic effects, increasing the risk of serotonin syndrome. This potentially life-threatening condition is characterized by neuromuscular excitation, autonomic instability, and altered mental status. Patients, especially those on higher doses or with other serotonergic agents, should be closely monitored for symptoms such as hyperthermia, rigidity, myoclonus, and tachycardia."
"Concomitant use of naratriptan, a 5-HT1B/1D receptor agonist, with bromocriptine, a dopamine D2 receptor agonist and ergot alkaloid derivative, may result in additive vasoconstriction due to synergistic stimulation of serotonin and dopamine receptors on vascular smooth muscle. This can lead to an increased risk of hypertensive crises, coronary artery vasospasm, myocardial ischemia, or cerebral ischemia, particularly in patients with underlying cardiovascular disease. Additionally, both drugs can elevate serotonin levels centrally, potentially raising the risk of serotonin syndrome, characterized by agitation, hyperthermia, and neuromuscular abnormalities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELETRIPTAN HYDROBROMIDE vs NARATRIPTAN, answered by our medical review team.
ELETRIPTAN HYDROBROMIDE is a 5-HT1 Agonist that works by Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibition of trigeminal nerve transmission.. NARATRIPTAN is a 5-HT1 Agonist that works by Selective serotonin 5-HT1B/1D receptor agonist; binds to these receptors on intracranial blood vessels and trigeminal sensory neurons, causing vasoconstriction and inhibition of neuropeptide release, thereby reducing migraine-related inflammation and pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELETRIPTAN HYDROBROMIDE and NARATRIPTAN depend on the specific clinical indication. These are both 5-HT1 Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELETRIPTAN HYDROBROMIDE is: 40 mg orally once, may repeat after 2 hours if headache recurs; maximum 80 mg/day.. The standard adult dose of NARATRIPTAN is: 2.5 mg orally at onset of migraine; may repeat after 4 hours if headache recurs, maximum 5 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELETRIPTAN HYDROBROMIDE and NARATRIPTAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELETRIPTAN HYDROBROMIDE is classified as Category D/X. Limited human data; animal studies show no teratogenicity at clinically relevant doses. First trimester: risk cannot be excluded; second/third trimester: no known increased risk. A. NARATRIPTAN is classified as Category D/X. FDA Pregnancy Category C. Animal studies show fetal toxicity (increased resorptions, skeletal anomalies) at maternotoxic doses. No adequate human studies. Avoid in first trimester . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.